The life sciences sector is undergoing a period of disruption unlike anything in its recent history — AI at scale, a $240 billion M&A surge, precision medicine, and a looming patent cliff that puts $370 billion in revenue at risk by 2032. This transformation is creating an urgent need for a new kind of leadership. Women in life sciences have never been more qualified to fill it. And most of them are still being blocked from the opportunity to try.